ReviewGut pathogens2025
Targeting autophagy and programmed cell death in neurological diseases via probiotic intervention.
Review in Gut pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The progressive degeneration in neuroprotection and cellular homeostasis related to aging significantly contributes to the beginning and development of neurodegenerative diseases (NDs) such as Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease. Autophagy as well as programmed cell death (PCD)—such as pyroptosis, apoptosis, and ferroptosis—play central roles in maintaining neuronal integrity and regulating brain aging. Recent discoveries underscore the essential function of the gut microbiota in modulating these pathways, with probiotic interventions emerging as promising modulators of autophagic flux and cell death signaling. This review explores the intricate crosstalk between probiotics, autophagy, and PCD mechanisms in the context of neurodegenerative diseases and aging. We highlight the capability of specific probiotics to influence molecular regulators such as Bcl-2 family proteins, caspases, and oxidative stress mediators, thereby restoring cellular balance and promoting neuronal survival. Additionally, we examine how probiotics metabolites act as signaling molecules that influence neuroinflammation, mitochondrial function, and epigenetic modifications. Emerging evidence supports the concept that probiotics may serve as non-invasive, adjunctive therapeutic agents capable of mitigating neurodegeneration by modulating autophagic and apoptotic responses. Understanding these mechanistic underpinnings paves the way for innovative microbiota-based involvements aimed at stimulating healthy brain aging and delaying the development of NDs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.